| [1] |
Guo Zehao, Zhang Junwang.
Role of PFDN and its subunits in tumorigenesis and tumor development
[J]. Journal of International Oncology, 2024, 51(6): 350-353.
|
| [2] |
Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.
Research progress of myeloid-derived suppressor cells in tumor angiogenesis
[J]. Journal of International Oncology, 2024, 51(1): 50-54.
|
| [3] |
Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui.
Role of ABRACL in the occurrence and development of malignant tumors
[J]. Journal of International Oncology, 2023, 50(9): 544-547.
|
| [4] |
Pan Shulan, Liu Chang, He Ping.
Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer
[J]. Journal of International Oncology, 2023, 50(8): 457-462.
|
| [5] |
Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.
Current status of research on exosomes in malignancies
[J]. Journal of International Oncology, 2023, 50(8): 484-488.
|
| [6] |
Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.
Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway
[J]. Journal of International Oncology, 2023, 50(7): 398-406.
|
| [7] |
Zeng Liwu, Du Yuqiang, Zhang Peng, Tao Kaixiong.
Progress in imaging evaluation of lateral lymph node metastasis in rectal cancer
[J]. Journal of International Oncology, 2023, 50(4): 248-251.
|
| [8] |
Liu Yujie, Zhao Zhiqiang, Wang Zicheng.
Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer
[J]. Journal of International Oncology, 2023, 50(12): 717-722.
|
| [9] |
Deng Lili, Duan Xingyu, Li Baozhong.
Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma
[J]. Journal of International Oncology, 2023, 50(12): 751-757.
|
| [10] |
Li Lixi, Wen Tingyu, Guan Xiuwen, Zhai Jingtong, Ma Fei.
Genetic susceptibility genes and clinical features of early-onset breast cancer
[J]. Journal of International Oncology, 2022, 49(4): 206-209.
|
| [11] |
Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong.
Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma
[J]. Journal of International Oncology, 2022, 49(10): 581-585.
|
| [12] |
Wu Yuping, Zhang Xiaoyu, Lu Keyi.
Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment
[J]. Journal of International Oncology, 2021, 48(9): 560-563.
|
| [13] |
Feng Zhiping, Yang Chuanzhou, Chen Ting, Zhu Jialun, Liu Chao, Lyu Juan, Lu Jianmei, Deng Zhiyong.
BRD4 inhibitor specifically inhibits the development of wild-type Kras differentiated thyroid carcinoma by regulating BRD4/miR-106b-5p/P21 axis
[J]. Journal of International Oncology, 2021, 48(8): 463-472.
|
| [14] |
Yu Jiaojiao, Wang Jun, Wang Likang, Yao Nan.
Advances in the amplification of HER2 in metastatic colorectal cancer
[J]. Journal of International Oncology, 2021, 48(4): 246-249.
|
| [15] |
Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan.
Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer
[J]. Journal of International Oncology, 2021, 48(11): 660-665.
|
